Exciting news from Haim Pharma Group! ✨
We’re proud to share that our project has been awarded a competitive grant from the Israel Innovation Authority. This support strengthens our mission to advance stabilized, low-dose psilocin as a novel therapeutic approach for neurodegenerative diseases.
A big thank you to our dedicated team, advisors, and partners who make this journey possible. We look forward to the next stage of development and to continuing our efforts to bring meaningful innovation to patients in need.
#Innovation #Neurodegeneration #LifeSciences #IsraelInnovationAuthority
Announcing our Clinical Advisor
📣 Announcing Our New Medical Advisor! 📣
hashtag#HaimPharmahashtag#ALShashtag#ClinicalTrialshashtag#MedicalAdvisorhashtag#Neurosilinhashtag#PatientDrivenResearchhashtag#DrRichardBedlack
Provisional patent application with the United States Patent and Trademark Office (USPTO)
Posted May 2025
ALS TDI Summit 2023
Posted 2024 ALSALS TDI Summit 2023
A word from one of our collaborators